• Profile
Close

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial

The Lancet Jan 12, 2019

Mehanna H, et al. - In this open-label randomized controlled phase 3 trial at 32 head and neck treatment centers in Ireland, the Netherlands, and the UK, researchers assessed 334 candidates to estimate the efficiency of radiotherapy plus cisplatin vs cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV) from Nov 12, 2012, to Oct 1, 2016. They observed no significant differences in overall all-grade toxicity of the two therapies. But, they found a notable difference between cisplatin and cetuximab in 2-year overall survival and 2-year recurrence. They suggested cisplatin plus radiotherapy as a standard of care for HPV-positive low-risk cases who could endure cisplatin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay